| Title |
Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
|
|---|---|
| Published in |
Archives of Dermatological Research, September 2015
|
| DOI | 10.1007/s00403-015-1593-8 |
| Pubmed ID | |
| Authors |
K. Reich, U. Mrowietz, M. A. Radtke, D. Thaci, S. J. Rustenbach, C. Spehr, M. Augustin |
| Abstract |
The German Psoriasis Registry PsoBest was conducted in 2008 in order to investigate the long-term outcomes and safety of systemic treatments for moderate-to-severe psoriasis. Safety analysis of antipsoriatic drugs with special focus on serious adverse events (SAE) for infections, malignancies and major cardiac events (MACE) was done. Nationwide non-interventional patient treatment registry conducted in 251 active dermatology centers. Until June 2012, n = 2444 patients [40 % female; mean age 47.3 (SD 14.1) years; mean duration of disease 18.2 (SD 14.7) years] were recruited, including n = 1791 patients (3842 patient years) with conventional systemic drugs and n = 908 (3442 patient years) with biological drugs. Mean PASI (Psoriasis Area and Severity Index) at inclusion was 14.7, mean DLQI (Dermatology Life Quality Index) 11.1, mean BMI (Body Mass Index) 28.2. The overall rate of SAE per 100 patient years were 1.3 (SD 0.9) per 100 patient years in conventional systemic and 1.5 (SD 1.2) in biologics (p > 0.5, no significant difference). The rates per 100 patient years for single severe adverse events were as follows (systemic/biologics): serious infections, 0.33/0.65 [CI (confidence interval) 0.13-0.54/0.35-0.98]; MACE, 0.56/0.77 (CI 0.29-0.97/0.41-1.31); malignancies (except non-melanoma skin cancer), 0.46/0.49 (CI 0.22-0.84/0.21-0.97). There were no significant differences between single drugs in any of the safety parameters. The conventional systemic and biologic drugs for psoriasis show satisfying safety under routine psoriasis care in Germany with respect to infections, MACE and malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 108 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 15 | 14% |
| Researcher | 15 | 14% |
| Student > Master | 14 | 13% |
| Student > Ph. D. Student | 11 | 10% |
| Student > Doctoral Student | 10 | 9% |
| Other | 17 | 15% |
| Unknown | 29 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Economics, Econometrics and Finance | 4 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Other | 10 | 9% |
| Unknown | 31 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2023.
All research outputs
#5,611,796
of 26,017,215 outputs
Outputs from Archives of Dermatological Research
#212
of 1,467 outputs
Outputs of similar age
#65,471
of 281,276 outputs
Outputs of similar age from Archives of Dermatological Research
#3
of 8 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,467 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,276 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.